GU Cancers 2019 | IMDC analysis: comparing the efficacy of first-line IO combination therapies in mRCC

Shaan Dudani

Shaan Dudani, MBChB, of the Tom Baker Cancer Centre, Alberta, Canada, presents preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) study, investigating the comparative efficacy of first-line immuno-oncology (IO) combination therapies for metastatic renal cell carcinoma (mRCC) patients. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco.

Share this video